Patent intelligence · US
US 8133861
Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
Patent details — US 8133861
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 13, 2012
- Expiration
- Mar 8, 2032
- Applicant
- Alseres Pharmaceuticals, Inc.
- Claims
- 2
- CPC classes
- A61K, A61K31/7076, A61K31/708, A61K45/06
Quick answer
US 8133861 (Systemic purine administration: modulating axonal outgrowth of central nervous system neurons) is held by Alseres Pharmaceuticals, Inc.. Status: granted. Granted Mar 13, 2012. Expires Mar 8, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Alseres Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K31/7076, A61K31/708, A61K45/06, A61K47/02, A61K9/0019
More from Alseres Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12409197
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 12214002
Compositions and methods for treating antibiotic resistance
granted -
US 12083151
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11918612
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11730775
Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
granted -
US 11701394
Compositions and methods for treating cholestatic disease
granted -
US 11666612
Network-based microbial compositions and methods
granted -
US 11464812
Synergistic bacterial compositions and methods of production and use thereof
granted
Frequently asked questions
What is US patent 8133861?
US 8133861 (Systemic purine administration: modulating axonal outgrowth of central nervous system neurons) is held by Alseres Pharmaceuticals, Inc.. Status: granted. Granted Mar 13, 2012. Expires Mar 8, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8133861?
Alseres Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 8133861 expire?
Our index shows an expiration date of Mar 8, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.